Author’s response to reviews

Title: CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.

Authors:

Rodrigo da Silva (rodrigoiverson@hotmail.com)
Daniela Cardozo (danielamcardozo@gmail.com)
Gisele Rodrigues (giseleolinto@gmail.com)
Caroline Souza-Araújo (caroline.natania@yahoo.com.br)
Natacha Migita (azussamigita@gmail.com)
Liliana Aparecida Andrade (lucci@unicamp.br)
Sophie Derchain (derchain@fcm.unicamp.br)
José Yunes (andres@boldrini.org.br)
Fernando Guimarães (fernando@caism.unicamp.br)

Version: 3 Date: 10 Oct 2017

Author’s response to reviews:

Dear Rebecca Strong,

We have addressed the Editor’s comments below. We have also carried out the essential editorial revision, necessary to fit the manuscript to the BMC Cancer patterns.

Please, do not hesitate to contact us if any further revision become necessary in the manuscript.

Best wishes.

Fernando Guimarães, PhD
Responses to Editor’s comments:

Editor Comment 1. Please clarify if consent to publish was obtained by the patient or her next of kin.

Response to comment 1. A written informed consent was provided by the patient, prior the sampling of blood and ascites, and an additional written informed consent for the publication of patient’s information was obtained from patient’s next of kin. This information was included in the manuscript, section “Consent for publication”.

Editor Comment 2. Please provide email addresses for all the co-authors on the title page.

Response to comment 2. Emails were provided on the title page.

Editor Comment 3. In the section 'Funding', please also describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Response to comment 3. São Paulo Research Foundation – FAPESP only granted financial support to the study. FAPESP did not participate in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. This information was provided in the manuscript, section “Funding”.